<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

High Efficacy of a Novel and Specific c-MET TKI in a Cohort of PDXs from Selected NSCLC and HCC Patients

Turning on c-Met signaling, through gene amplification, activating mutations or interaction with its only known high affinity ligand - hepatocyte growth factor (HGF), is associated with invasive progression of many types of cancers, such as papillary renal, gastric, hepatocellular (HCC) and non-small cell lung carcinoma (NSCLC).